Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 36.29 Million SEK | 334.77% |
| 2022 | 8.34 Million SEK | -87.19% |
| 2021 | 65.17 Million SEK | 552.5% |
| 2020 | -14.4 Million SEK | -217.25% |
| 2019 | -4.54 Million SEK | -1215.94% |
| 2018 | -345 Thousand SEK | -27.31% |
| 2017 | -271 Thousand SEK | -1025.7% |
| 2016 | -24.07 Thousand SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 4.78 Million SEK | 5.03% |
| 2024 Q2 | 7.2 Million SEK | 50.64% |
| 2023 Q2 | 25.92 Million SEK | 2229.65% |
| 2023 FY | 36.29 Million SEK | 334.77% |
| 2023 Q4 | 4.55 Million SEK | -3.08% |
| 2023 Q3 | 4.7 Million SEK | -81.87% |
| 2023 Q1 | 1.11 Million SEK | 100.9% |
| 2022 Q1 | - SEK | 100.0% |
| 2022 FY | 8.34 Million SEK | -87.19% |
| 2022 Q2 | 8.75 Million SEK | 0.0% |
| 2022 Q4 | 554 Thousand SEK | 157.83% |
| 2022 Q3 | -958 Thousand SEK | -110.94% |
| 2021 Q2 | 63.55 Million SEK | 234.01% |
| 2021 Q1 | 19.02 Million SEK | 0.0% |
| 2021 FY | 65.17 Million SEK | 552.5% |
| 2021 Q3 | 22.68 Million SEK | -64.31% |
| 2021 Q4 | -40.08 Million SEK | -276.73% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | -14.4 Million SEK | -217.25% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | -4.54 Million SEK | -1215.94% |
| 2018 FY | -345 Thousand SEK | -27.31% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | -271 Thousand SEK | -1025.7% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | -24.07 Thousand SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 122.59% |
| Ziccum AB (publ) | -23.28 Million SEK | 255.883% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 89.519% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 13.133% |
| Mendus AB (publ) | 28.48 Million SEK | -27.423% |
| Genovis AB (publ.) | 54 Million SEK | 32.781% |
| Intervacc AB (publ) | -13.79 Million SEK | 363.151% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -1571.994% |
| Active Biotech AB (publ) | -1.67 Million SEK | 2267.104% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -264.338% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -35.338% |
| Aptahem AB (publ) | 2.63 Million SEK | -1279.85% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 1161.064% |
| Kancera AB (publ) | -1.96 Million SEK | 1947.277% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -47041.558% |
| Fluicell AB (publ) | 1.73 Million SEK | -1988.55% |
| Saniona AB (publ) | 11.78 Million SEK | -208.115% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 809.38% |
| Biovica International AB (publ) | 6.87 Million SEK | -427.832% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 255.903% |
| AcouSort AB (publ) | 8.38 Million SEK | -332.698% |
| Xintela AB (publ) | 78 Thousand SEK | -46437.179% |
| Abliva AB (publ) | -35.66 Million SEK | 201.783% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 124.71% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -1193.16% |
| OncoZenge AB (publ) | 3000.00 SEK | -1209866.667% |
| Amniotics AB (publ) | -1.93 Million SEK | 1980.777% |
| 2cureX AB (publ) | -37.48 Million SEK | 196.831% |
| CombiGene AB (publ) | -21.29 Million SEK | 270.492% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 8681.324% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 96.787% |
| Camurus AB (publ) | 1.58 Billion SEK | 97.703% |
| Corline Biomedical AB | 28.38 Million SEK | -27.903% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 129.575% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 205.474% |
| I-Tech AB | 27.56 Million SEK | -31.68% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 48.839% |
| Cyxone AB (publ) | 2.61 Million SEK | -1290.234% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -966.676% |
| Biosergen AB | -456 Thousand SEK | 8060.307% |
| Cantargia AB (publ) | -3.45 Million SEK | 1151.84% |
| NextCell Pharma AB | -43.74 Million SEK | 182.973% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 494.812% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -223.57% |
| Nanologica AB (publ) | -76 Thousand SEK | 47861.842% |
| SynAct Pharma AB | -778 Thousand SEK | 4765.681% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 18907.772% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 380.909% |
| Lipum AB (publ) | 53 Thousand SEK | -68388.679% |
| BioInvent International AB (publ) | 71.46 Million SEK | 49.204% |
| Alzinova AB (publ) | 19.87 Million SEK | -82.646% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -2381.101% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 242093.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -2089.324% |
| Simris Alg AB (publ) | 2 Million SEK | -1708.62% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 1113.939% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | -2.574% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 3560.343% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -1058.602% |